Retatrutide is a next-generation GLP-1, GIP, and glucagon receptor triple-agonist peptide — the first of its kind to target all three receptors simultaneously. This triple mechanism makes it significantly more effective at promoting fat loss and metabolic regulation than single or dual-agonist peptides like Semaglutide or Tirzepatide.

It is currently available from Alluvi Healthcare UK for research and laboratory evaluation purposes, supplied in controlled, lab-tested batches.

Alluvi Healthcare offers a focused range of research-grade peptide products:

• Retatrutide 20mg ×2 Bundle — Best-value research bundle, pre-measured and verified
• Retatrutide 20mg Precision Pen — Pre-filled, sleek design for controlled research settings
• Alluvi Gummies — Peptide-based weight loss and wellness supplements
• Peptides for Weight Loss — Full range of metabolic support compounds

Browse the full product range on our shop.

Retatrutide is a triple-agonist (GLP-1 + GIP + glucagon), while Semaglutide is a single-agonist and Tirzepatide is a dual-agonist. Clinical data suggests Retatrutide achieves significantly greater weight loss — up to 22.5% body weight reduction compared to approximately 15% with Tirzepatide and 12–15% with Semaglutide.

Read the full comparative analysis on Retatrutide vs other GLP-1 agonists.

Alluvi Gummies are peptide-based supplement gummies designed to support weight loss and overall wellness. They’re formulated as a convenient, accessible alternative to injection-based peptide compounds — suitable for daily supplementation alongside a structured wellness or research protocol.

View the Alluvi Gummies product page for full details.

Dosage requirements depend on individual research protocols. Clinical trials have used a dose-escalation approach, starting low and increasing gradually over several weeks to minimise gastrointestinal side effects.

High-dose protocols (up to 12mg weekly) produced the highest average weight loss of 18.3kg over 48 weeks. For a comprehensive dosage overview, refer to published clinical literature on PubMed.

Commonly reported side effects in clinical trials include:

• Nausea (most common, typically mild and transient)
• Reduced appetite and early satiety
• Gastrointestinal discomfort (bloating, constipation, or diarrhoea)
• Mild fatigue, particularly in early weeks

Most side effects were dose-dependent and reduced with gradual dose escalation. Read the full Retatrutide safety and management guide for detailed information.

Data from Phase 2 clinical trials published in the New England Journal of Medicine shows:

• 22.5% average total body weight reduction
• 18.3kg average weight loss over 48 weeks on high-dose protocol
• 600 calorie natural daily intake reduction through appetite suppression
• +28% increase in energy levels reported within the first 4 weeks

Yes. All Alluvi Healthcare products undergo rigorous independent lab testing before dispatch. Every batch is verified for purity, potency, and composition with full documentation available upon request.

We maintain transparent labelling across all products — no hidden ingredients, no unverified claims. You always know exactly what you’re working with.

All UK orders are dispatched quickly from our UK facility. Standard tracked delivery typically arrives within 2–4 working days. Express options may be available at checkout.

Orders are packed in secure, discreet unmarked packaging with no product branding visible externally.

Yes. All orders are dispatched in plain, unmarked packaging with no external branding, product names, or labelling visible. Your privacy is a priority at every stage of the order process.

Alluvi Healthcare is a UK-based supplier primarily serving UK customers. For international enquiries, please contact our support team who can advise on availability and any applicable regulations in your country.

Yes. The Alluvi app, developed by Alluvial Labs, is available on the App Store. It provides a seamless experience for tracking health metrics, managing research protocols, and better health management.

Yes. UK-based clinical studies on Retatrutide are being conducted through the National Institute for Health Research (NIHR), investigating its efficacy in treating obesity and metabolic disorders.

If you’re interested in participating in clinical trials, visit the NIHR’s website for eligibility criteria and how to register.

The primary clinical data is published in the New England Journal of Medicine (NEJM). Detailed research summaries are also available on PubMed.

A full overview of Retatrutide’s clinical profile, mechanism, and ongoing research can be found via its Wikipedia compound page.

Retatrutide is available in the UK for research and laboratory use. It is not currently an approved prescription medicine in the UK for consumer use.

The MHRA actively monitors the market for illegal and unapproved weight loss medicines. Alluvi Healthcare operates with full transparency and proper documentation. Always purchase from verified, reputable UK suppliers.

Alluvi Healthcare is a UK-based, registered healthcare brand with a clear commitment to quality, safety, and transparency. Key trust markers include:

• Independent lab testing on every batch
• Full, transparent product labelling and documentation
• Verified research partnerships with recognised organisations
• Active social presence and contactable expert support team
• Compliance with UK regulatory frameworks